Beijing Luzhu Biotechnology Co (HKSE:02480) Cash, Cash Equivalents, Marketable Securities : HK$818.34 Mil (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co Cash, Cash Equivalents, Marketable Securities?

Beijing Luzhu Biotechnology Co's quarterly cash, cash equivalents, marketable securities increased from Jun. 2022 (HK$0.00 Mil) to Dec. 2022 (HK$649.53 Mil) and increased from Dec. 2022 (HK$649.53 Mil) to Jun. 2023 (HK$818.34 Mil).

Beijing Luzhu Biotechnology Co's annual cash, cash equivalents, marketable securities increased from . 20 (HK$0.00 Mil) to Dec. 2021 (HK$691.08 Mil) but then declined from Dec. 2021 (HK$691.08 Mil) to Dec. 2022 (HK$649.53 Mil).

Beijing Luzhu Biotechnology Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co Cash, Cash Equivalents, Marketable Securities Chart

Beijing Luzhu Biotechnology Co Annual Data

Trend

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

691.08

649.53

665.38

Beijing Luzhu Biotechnology Co Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Cash, Cash Equivalents, Marketable Securities	691.08	-	649.53	818.34	665.38

Beijing Luzhu Biotechnology Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Beijing Luzhu Biotechnology Co (HKSE:02480) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Beijing Luzhu Biotechnology Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Luzhu Biotechnology Co (HKSE:02480) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN

Website

http://www.luzhubiotech.com

Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.

Executives

Ma Jianan	2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si	2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo	2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo	2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin	2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
China Construction Bank Corporation	2201 Interest of corporation controlled by you
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Peng Ling	2201 Interest of corporation controlled by you
Zhang Yanping	2202 Interest of your spouse
Kong Jian	2101 Beneficial owner
Ma Biao	2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co (HKSE:02480) Headlines

No Headlines